-
Access departments struggling with dwindling cash collections may find that some simple incentives can work wonders. On the other hand, there are some potential pitfalls to consider.
-
The incretin class of medications (exenatide, liraglutide, sitagliptin, saxagliptin) all share the favorable quality of not being associated with weight gain.
-
A recombinant, polyethylene glycol (PEG) mammalian urate oxidase (uricase) has been approved by the FDA for treatment of hyperuricemia. Uricase metabolizes urate to allantoin, a water-soluble metabolite, which is cleared renally. Pegliticase is marketed by Savient Pharmaceuticals as Krystexxa™.
-
A systematic review shows that the three classical symptoms of paroxysmal cough, post-tussive emesis, and inspiratory whoop are helpful for the diagnosis, but cannot be relied upon to rule in or rule out pertussis as the cause of a chronic cough.
-
Initiating treatment for hypercholesterolemia at age 30 years instead of age 60 years might very well prevent not just 30% of the CAD events as occurred in the 5-year statin trials, but perhaps as many as 60% of the CAD events lifetime.
-
-
In a very large Norwegian study, use of screening mammography was associated with a reduction in the rate of death from breast cancer, but the screening itself accounted for only about a third of the total reduction in death rate.
-
FDA Advisory Committee recommends approval of dabigatran, safety of proton pump inhibitors, effectiveness of glucosamine and chondroitin, FDA Actions.
-
A unique study pairing the use of a standard SSRI and SAMe against major depression in subjects who had not responded adequately to SSRI monotherapy suggests safety and significant efficacy over a 6-week trial period.
-
Results of this methodologically sound trial strongly suggest that moderate-dose B vitamin therapy has a protective effect against the rapidly progressive brain atrophy commonly seen in elderly people with mild cognitive impairment (MCI). The intervention was safe and effective over a 2-year time frame, and shows promise for slowing the inexorable progression of MCI to frank dementia.